NGT3 (Next Generation Technology) is an early-stage investment entity structured as a venture capital fund, focused on medical device and life science technologies and holder of a government franchise to operate a technology incubator for a period of 8 years.
NGT3 enjoys a high leverage (85%) through non-dilutive grant from Israel’s Chief Scientist Office at the Ministry of Economy (OCS).
NGTᶾ has extensive practical experience throughout the spectrum of product life cycle development. From identifying high‐potential technologies, overseeing goal‐directed research and development efforts, to encouraging successive iterations in order to produce innovative products that will be highly valued in the marketplace. NGT3’s know‐how is present every step of the way, providing a steady experienced hand, guiding the product’s concept development as it moves and evolves from the early stages of feasibility, preclinical and clinical studies, through to the goal of bringing an innovative, new product to the markets that need it;
The management team and partners of NGT3, individually and collectively, have extensive track records with proven performance in the arena of creating and growing financially‐healthy companies with successful product lines.
NGT3 invests in early-stage medical device/life science start-up companies with a well-defined unmet market need, large potential market, novel technologies with strong IP coverage and strong capable management.
Strategically located in Nazareth, NGT3 benefits from the untapped potential of scientists and researchers in the Arab sector while being fully integrated into Israel’s world-renowned technological creativity and entrepreneurial eco-system.
Social agenda
Technology
ROI
